Trial Profile
A Phase 2A Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs ARB 1467 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Arbutus Biopharma
- 01 Jul 2018 Status changed from active, no longer recruiting to completed.
- 02 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2017 Results (n=24) assessing pharmacokinetics and exploratory exposure response presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.